Wall Street analysts expect AbbVie Inc (NYSE:ABBV) to announce $2.24 earnings per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for AbbVie’s earnings, with the lowest EPS estimate coming in at $2.20 and the highest estimate coming in at $2.27. AbbVie reported earnings per share of $1.90 during the same quarter last year, which indicates a positive year-over-year growth rate of 17.9%. The company is scheduled to report its next earnings report on Friday, January 24th.

According to Zacks, analysts expect that AbbVie will report full year earnings of $8.93 per share for the current year, with EPS estimates ranging from $8.87 to $9.00. For the next financial year, analysts expect that the firm will report earnings of $9.41 per share, with EPS estimates ranging from $9.35 to $9.46. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for AbbVie.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, November 1st. The company reported $2.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.29 by $0.04. The company had revenue of $8.48 billion during the quarter, compared to analyst estimates of $8.37 billion. AbbVie had a negative return on equity of 155.71% and a net margin of 9.90%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the company earned $2.14 EPS.

ABBV has been the subject of a number of recent research reports. Citigroup raised shares of AbbVie from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $87.00 to $90.00 in a research note on Thursday, September 26th. ValuEngine upgraded shares of AbbVie from a “strong sell” rating to a “sell” rating in a research note on Monday, September 30th. Cowen set a $90.00 price objective on shares of AbbVie and gave the company a “buy” rating in a research note on Tuesday, September 24th. TheStreet downgraded shares of AbbVie from a “b-” rating to a “c” rating in a research note on Monday, August 26th. Finally, Piper Jaffray Companies increased their price objective on shares of AbbVie from $81.00 to $90.00 in a research note on Friday, November 1st. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $84.88.

In other AbbVie news, Vice Chairman Laura J. Schumacher acquired 25,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were purchased at an average price of $70.42 per share, with a total value of $1,760,500.00. Following the completion of the transaction, the insider now owns 164,838 shares in the company, valued at $11,607,891.96. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Nicholas Donoghoe acquired 7,525 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The shares were acquired at an average cost of $66.19 per share, for a total transaction of $498,079.75. Following the transaction, the senior vice president now owns 13,090 shares of the company’s stock, valued at approximately $866,427.10. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 88,077 shares of company stock valued at $4,401,551. Insiders own 0.08% of the company’s stock.

Several large investors have recently added to or reduced their stakes in ABBV. Arbor Wealth Management LLC bought a new position in shares of AbbVie in the second quarter valued at approximately $28,000. Lowe Wealth Advisors LLC raised its stake in AbbVie by 206.7% in the 2nd quarter. Lowe Wealth Advisors LLC now owns 460 shares of the company’s stock valued at $33,000 after acquiring an additional 310 shares during the period. Horrell Capital Management Inc. bought a new stake in AbbVie in the 2nd quarter valued at $33,000. TD Capital Management LLC bought a new stake in AbbVie in the 2nd quarter valued at $33,000. Finally, Financial Gravity Wealth Inc. raised its stake in AbbVie by 82.9% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 503 shares of the company’s stock valued at $37,000 after acquiring an additional 228 shares during the period. 68.38% of the stock is currently owned by institutional investors.

NYSE:ABBV traded up $3.00 during trading hours on Friday, reaching $85.01. The company’s stock had a trading volume of 514,519 shares, compared to its average volume of 7,526,836. The company has a market capitalization of $121.00 billion, a P/E ratio of 10.75, a price-to-earnings-growth ratio of 2.04 and a beta of 0.98. AbbVie has a 12 month low of $62.66 and a 12 month high of $94.98. The stock has a 50 day moving average price of $76.02 and a two-hundred day moving average price of $73.45.

The firm also recently disclosed a — dividend, which will be paid on Friday, November 15th. Stockholders of record on Tuesday, October 15th will be given a dividend of $1.07 per share. The ex-dividend date is Friday, October 11th. This represents a dividend yield of 6.4%. AbbVie’s dividend payout ratio (DPR) is 54.11%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Recommended Story: What is the price-sales ratio?

Get a free copy of the Zacks research report on AbbVie (ABBV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.